ReviewBioscience reports2026
MUC17 and the intestinal glycocalyx: structure, regulation, and barrier function in health and disease.
Review in Bioscience reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The intestinal epithelial surface is protected by a multilayered barrier system that includes secreted mucus and a membrane-bound glycocalyx. While gel-forming mucins have been extensively studied, the transmembrane mucins that form the enterocyte glycocalyx remain less well understood. MUC17 has emerged as a dominant and functionally important transmembrane mucin of the small intestinal brush border, where its large, extensively O-glycosylated extracellular domain forms a dense, hydrated barrier between luminal microbes and the epithelial membrane. This review summarizes current knowledge of MUC17 biology, from genomic organization and protein architecture to glycosylation, trafficking, developmental regulation, and barrier function. Particular emphasis is placed on how MUC17 contributes to size-selective exclusion, bacterial segregation, and host-microbe homeostasis. This review further discusses the developmental establishment of the MUC17-rich enterocyte glycocalyx during the suckling-weaning transition and covers the mechanisms that regulate MUC17 localization and dynamics in epithelial cells, including apical targeting, membrane retention, recycling, turnover, and responses to inflammatory cues. Finally, the review examines the consequences of altered MUC17 expression or function, with particular emphasis on glycocalyx barrier defects, host-microbe interactions, bacterial access to the epithelium, and the relevance of MUC17 dysfunction to Crohn's disease and experimental models of intestinal infection. Together, the review positions MUC17 as a central structural and functional component of the intestinal glycocalyx and an underexplored therapeutic axis for restoring epithelial barrier integrity in intestinal disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.